Biology-driven cancer drug development: back to the future

od Lord, Christopher J, Ashworth, Alan
Izdano 2010

PARP Inhibitors: The First Synthetic Lethal Targeted Therapy

od Lord, Christopher J., Ashworth, Alan
Izdano u Science (2017)

Nuclear envelope–vacuole contacts mitigate nuclear pore complex assembly stress

od Lord, Christopher L., Wente, Susan R.
Izdano u J Cell Biol (2020)

The Highly Conserved COPII Coat Complex Sorts Cargo from the Endoplasmic Reticulum and Targets It to the Golgi

od Lord, Christopher, Ferro-Novick, Susan, Miller, Elizabeth A.
Izdano 2013

Nup100 regulates Saccharomyces cerevisiae replicative life span by mediating the nuclear export of specific tRNAs

od Lord, Christopher L., Ospovat, Ophir, Wente, Susan R.
Izdano u RNA (2017)

Integrative analysis of large-scale loss-of-function screens identifies robust cancer-associated genetic interactions

od Lord, Christopher J, Quinn, Niall, Ryan, Colm J
Izdano u eLife (2020)

NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells

od Mendes-Pereira, Ana M., Lord, Christopher J., Ashworth, Alan
Izdano 2012

Driver oncogenes but not as we know them - targetable fusion genes in breast cancer

od Natrajan, Rachael, Tutt, Andrew N. J., Lord, Christopher J.
Izdano u Cancer Discov (2018)

CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer

od Bridgett, Stephen, Campbell, James, Lord, Christopher J., Ryan, Colm J.
Izdano u Cell Syst (2017)

An RNA interference screen for identifying downstream effectors of the p53 and pRB tumour suppressor pathways involved in senescence

od Rovillain, Emilie, Mansfield, Louise, Lord, Christopher J, Ashworth, Alan, Jat, Parmjit S
Izdano 2011

Directing the use of DDR kinase inhibitors in cancer treatment

od Brandsma, Inger, Fleuren, Emmy D.G., Williamson, Chris T., Lord, Christopher J.
Izdano u Expert Opin Investig Drugs (2017)

A Machine-Learning Tool Concurrently Models Single Omics and Phenome Data for Functional Subtyping and Personalized Cancer Medicine

od Nyamundanda, Gift, Eason, Katherine, Guinney, Justin, Lord, Christopher J., Sadanandam, Anguraj
Izdano u Cancers (Basel) (2020)

Altering nuclear pore complex function impacts longevity and mitochondrial function in S. cerevisiae

od Lord, Christopher L., Timney, Benjamin L., Rout, Michael P., Wente, Susan R.
Izdano u J Cell Biol (2015)

A Compendium of Co-regulated Protein Complexes in Breast Cancer Reveals Collateral Loss Events

od Ryan, Colm J., Kennedy, Susan, Bajrami, Ilirjana, Matallanas, David, Lord, Christopher J.
Izdano u Cell Syst (2017)

Beyond DNA repair: the novel immunological potential of PARP inhibitors

od Chabanon, Roman M., Soria, Jean-Charles, Lord, Christopher J., Postel-Vinay, Sophie
Izdano u Mol Cell Oncol (2019)

DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells

od Gudmundsdottir, Katrin, Lord, Christopher J, Witt, Emily, Tutt, Andrew N J, Ashworth, Alan
Izdano 2004

Structural basis for recruitment of BRCA2 by PALB2

od Oliver, Antony W, Swift, Sally, Lord, Christopher J, Ashworth, Alan, Pearl, Laurence H
Izdano 2009

Structural basis for recruitment of BRCA2 by PALB2

od Oliver, Antony W, Swift, Sally, Lord, Christopher J, Ashworth, Alan, Pearl, Laurence H
Izdano u EMBO Rep (2017)

Ultrasound-guided muscle biopsy: a practical alternative for investigation of myopathy

od Raithatha, Anish, Ashraghi, Mohammad Reza, Lord, Christopher, Limback-Stanic, Clara, Viegas, Stuart, Amiras, Dimitri
Izdano u Skeletal Radiol (2020)

Complementary genetic screens identify the E3 ubiquitin ligase CBLC, as a modifier of PARP inhibitor sensitivity

od Frankum, Jessica, Moudry, Pavel, Brough, Rachel, Hodny, Zdenek, Ashworth, Alan, Bartek, Jiri, Lord, Christopher J.
Izdano u Oncotarget (2015)